- Home
- AUC vs ELTX Comparison
AUC vs ELTX Comparison
Compare AUC & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AUC | ELTX |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | 6 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.6M | 63.3M |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | AUC | ELTX |
|---|---|---|
| Price | $7.24 | $2.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 3.0K | ★ 281.3K |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,301,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.82 | $2.17 |
| 52 Week High | $8.58 | $16.00 |
Technical Indicators
Market Signals| Indicator | AUC | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.41 | 22.25 |
| Support Level | $6.07 | N/A |
| Resistance Level | $7.16 | $3.32 |
| Average True Range (ATR) | 0.48 | 0.13 |
| MACD | 0.05 | -0.04 |
| Stochastic Oscillator | 60.42 | 4.33 |
Price Performance
Historical ComparisonAbout AUC ATIF Holdings Limited Ordinary Shares
ATIF Holdings Ltd is a consulting company. It provides financial consulting services to small and medium-sized enterprises. It operates in one operating segment, which is the consulting service business. The company prominently generated revenues from consulting services to its clients. Geographically, the maximum revenue is derived from Hong Kong.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.